Medidata, the leading global provider of cloud-based solutions for clinical research, announced that it has signed a multi-year enterprise deal with Hanmi Pharmaceutical, one of South Korea's leading drug makers.

A Medidata customer since 2013, the Seoul-based pharmaceutical company is expanding its technology partnership with Medidata, becoming the first Korean company to incorporate the Medidata Clinical Cloud into all clinical trials across its drug development programmes.

“Our expanded partnership with Medidata is a key example of the aggressive investments we’re making in R&D to grow our business globally and accelerate drug development, so that we can more quickly and efficiently develop innovative new treatments for patients,” said Ji-Woong Son, vice president of Hanmi Pharmaceutical. “We are very pleased to collaborate with Medidata, the global leader in clinical trial technology. By leveraging their cloud platform, analytics and deep life sciences industry expertise, we can better ensure productivity and accuracy in our research efforts and the high quality of our clinical data.”

In the last five years, Hanmi has more than doubled its investment in R&D—from 84 billion won in 2011 to 187 billion won in 2015—to accelerate R&D innovation and establish itself as a global market leader. The company is focused on developing novel therapies to advance care in diabetes, obesity, oncology and auto-immunology.

Hanmi has been using Medidata’s unified electronic data capture, management and reporting tool (Medidata Rave) and medical coding capabilities (Medidata Coder) in a number of its studies since 2013. The company will now expand its use of both solutions, as well as leverage Medidata’s Trial Assurance offering, across its entire clinical development program. A comprehensive solution which evaluates the quality of clinical and lab data, Medidata Trial Assurance calls upon powerful statistical algorithms to automatically mine the clinical database of each study—identifying anomalies, outliers, potential fraud and misconduct, and procedural issues to mitigate risk and optimize trial results.

“As new medical advances in Korea make their way to global markets, there’s been an increasing demand for data standardization and more efficient clinical trials across the Asia-Pacific region,” said Edwin Ng, Medidata’s vice president of APeJ (Asia Pacific except Japan). “Our cloud technology platform is meeting this demand and powering innovation for Hanmi. We’re excited to expand our partnership and look forward to supporting them as they develop novel biologics, chemical entities and drugs for patients on a global scale.”

Since its establishment in 1973, Hanmi Pharmaceutical has become Korea’s very first global pharmaceutical company through Korean R&D strategy starting from synthesis technology development continues to generic, IMD/FDC and innovative new drugs.

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics.